NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon today reported its first quarter revenues were up 2 percent year over year.

The company reported DKK32.5 million ($6.0 million) in revenues for the three months ended March 31, compared to DKK31.8 million in the year-ago quarter. It attributed the gain to continued organic growth in its Life Sciences product sales, which rose 5 percent year over year, driven by new products. Exiqon's Services business was down 19 percent year over year during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.